Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
131.8 USD | -0.36% | -1.38% | +36.70% |
Sales 2024 * | 1.9B 2.59B | Sales 2025 * | 2.76B 3.78B | Capitalization | 12.46B 17.03B |
---|---|---|---|---|---|
Net income 2024 * | 266M 364M | Net income 2025 * | 883M 1.21B | EV / Sales 2024 * | 6.02 x |
Net cash position 2024 * | 1.03B 1.41B | Net cash position 2025 * | 2.54B 3.48B | EV / Sales 2025 * | 3.59 x |
P/E ratio 2024 * |
40.8
x | P/E ratio 2025 * |
13
x | Employees | 1,314 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.11% |
Latest transcript on Sarepta Therapeutics, Inc.
1 day | -0.36% | ||
1 week | -1.38% | ||
Current month | +4.07% | ||
1 month | +5.92% | ||
3 months | +3.90% | ||
6 months | +65.92% | ||
Current year | +36.70% |
Managers | Title | Age | Since |
---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 17-06-25 |
Ian Estepan
DFI | Director of Finance/CFO | 48 | 14-12-31 |
Bilal Arif
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 17-06-25 |
M. Wilsey
CHM | Chairman | 71 | 09-03-30 |
Richard Barry
BRD | Director/Board Member | 65 | 15-06-01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.63% | 0 M€ | -2.17% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 131.8 | -0.36% | 735,589 |
24-05-09 | 132.3 | -0.21% | 1,279,163 |
24-05-08 | 132.6 | -2.54% | 1,579,021 |
24-05-07 | 136 | +0.74% | 2,003,305 |
24-05-06 | 135 | +1.03% | 823,447 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+36.70% | 12.46B | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+295.70% | 8.12B |
- Stock Market
- Equities
- SRPT Stock